

Supplemental Table 1. Nine treatment-expanded TCR clonotypes shared between PBMC and TILs in top 20 TCR clonotypes of pre-PBMC or pre-TIL

PX ID	CDR3 region amino_acid	pre_TIL_Freq	pre_TIL_Rank	post_TIL_Freq	post_TIL_Rank	Ratio_TIL	pre_PBMC_Freq	pre_PBMC_Rank	post_PBMC_Freq	post_PBMC_Rank	Ratio_PBMC
6	CASSPPSRDYVSYEQYF	1.908%	3	2.263%	1	1.186	0.31%	8	0.409%	8	1.321
16	CASTRTGYPAGPHNEQFF	1.033%	4	2.401%	3	2.324	2.432%	2	3.68%	2	1.513
16	CASSLSGGGEQYF	0.302%	12	0.913%	8	3.027	0.194%	16	0.362%	10	1.871
24	CASSSLRGPEDYGYTF	0.802%	1	3.142%	1	3.919	0.679%	2	1.222%	3	1.799
24	CASSDRGDPSEPQHF	0.55%	7	0.799%	12	1.452	2.832%	1	3.549%	1	1.253
24	CASSSHYPTDTQYF	0.345%	11	1.29%	7	3.736	0.287%	6	0.52%	5	1.814
24	CAISDPRDSYEQYF	0.274%	13	0.825%	11	3.007	0.192%	11	0.224%	18	1.168
24	CASSYSTSGQETQYF	0.154%	20	0.541%	17	3.507	0.184%	12	0.505%	6	2.736
27	CASSFHAGAGNTIYF	0.668%	5	1.306%	6	1.955	0.629%	5	0.967%	6	1.537
27	CASSPPTGAISYEQYF	0.339%	13	0.532%	23	1.568	0.221%	20	0.353%	13	1.593

Patient ID indicates the patient who harbors a shared expanded top TCR clonotype. Patient 6 is a non-responder and patient 16, 24, and 27 are responders (in red fonts).

Supplemental Table 2. Eighteen treatment-expanded TCR clonotypes shared between PBMC and TILs in top 50 TCR clonotypes of pre-PBMC or pre-TIL

No	PX ID	CDR3 region amino_acid	pre_TIL_Freq	pre_TIL_Rank	post_TIL_Freq	post_TIL_Rank	Ratio_TIL	pre_PBMC_Freq	pre_PBMC_Rank	post_PBMC_Freq	post_PBMC_Rank	Ratio_PBMC
1	6	CASSPPSRDYVSYEQYF	1.908%	3	2.263%	1	1.186	0.31%	8	0.409%	8	1.321
2	10	CASSQDSGNSNQPQHF	0.529%	5	0.713%	11	1.349	0.061%	34	0.069%	29	1.119
3	13	CAISTGDGNQPQHF	0.775%	2	1.444%	3	1.864	0.263%	24	0.284%	22	1.078
4	13	CASSLEGQGVLPQHF	0.66%	4	1.735%	2	2.63	0.14%	36	0.16%	32	1.137
5	13	CASSEGTSGSYEQYF	0.295%	15	0.384%	25	1.303	0.118%	41	0.206%	29	1.756
6	14	CASETGFTGNTIYF	0.298%	21	0.87%	3	2.921	0.166%	33	0.343%	22	2.064
7	15	CASSLSHDAFF	0.689%	20	0.887%	3	1.287	0.163%	23	0.183%	29	1.117
8	16	CASTRTGYPAGPHNEQFF	1.033%	4	2.401%	3	2.324	2.432%	2	3.68%	2	1.513
9	16	CASSLSGGGEQYF	0.302%	12	0.913%	8	3.027	0.194%	16	0.362%	10	1.871
10	24	CASSSLRGPEDYGYTF	0.802%	1	3.142%	1	3.919	0.679%	2	1.222%	3	1.799
11	24	CASSDRGDPSEPQHF	0.55%	7	0.799%	12	1.452	2.832%	1	3.549%	1	1.253
12	24	CASSSHYPTDTQYF	0.345%	11	1.29%	7	3.736	0.287%	6	0.52%	5	1.814
13	24	CAISDPRDSYEQYF	0.274%	13	0.825%	11	3.007	0.192%	11	0.224%	18	1.168
14	24	CASSYSTSGQETQYF	0.154%	20	0.541%	17	3.507	0.184%	12	0.505%	6	2.736
15	27	CASSFHAGAGNTIYF	0.668%	5	1.306%	6	1.955	0.629%	5	0.967%	6	1.537
16	27	CASSPPTGAISYEQYF	0.339%	13	0.532%	23	1.568	0.221%	20	0.353%	13	1.593
17	27	CASSYGGSYEQYF	0.174%	26	0.286%	41	1.64	0.162%	25	0.211%	22	1.296
18	27	CASSVDIQQPQHF	0.135%	44	0.177%	60	1.313	0.087%	47	0.094%	39	1.082

Patient ID indicates the patient who harbors a shared expanded top TCR clonotype. Patient 6, 10, 13, 14 and 15 are non-responders and patient 16, 24, and 27 are responders (in red fonts).